Real-world before-and-after evaluation of AI support for lung cancer diagnosis at three US lung nodule clinics.
Authors
Affiliations (4)
Affiliations (4)
- Thoracic Surgery and Lung Center of Excellence, Jupiter Medical Center, Jupiter, Florida, United States of America.
- Interventional Pulmonology, AtlantiCare Regional Medical Center, Atlantic City, New Jersey, United States of America.
- Department of Medicine, Division of Pulmonary, Critical Care, and Sleep Medicine, University of Connecticut School of Medicine, Farmington, Connecticut, United States of America.
- Optellum Ltd, Oxford, United Kingdom.
Abstract
Health systems and payers require evidence that artificial intelligence (AI)-enabled decision support improves care delivery. Integrating AI into lung nodule management pathways may streamline workflows, improve identification and triage of patients with pulmonary nodules, and enable earlier lung cancer diagnosis. Yet real-world evidence of clinical utility remains limited. This study evaluated the impact of implementing commercially available AI software to support the lung nodule and lung cancer care pathway across three US health systems. A real-world before-and-after study compared clinic activity during matched 12.5-month pre-implementation and post-implementation periods at three US lung nodule clinics. Primary outcomes were the number of new patients and the number of patients undergoing at least one invasive procedure. Secondary outcomes were numbers of lung cancers and early-stage (stages I-II) lung cancers, and time from baseline CT to diagnosis. Analyses used Wilcoxon signed-rank and Mann-Whitney U tests, with medians and interquartile ranges (IQRs) reported for continuous measures. Across sites, new patients increased from 138 before to 232 after implementation, equivalent to 11.0 to 18.6 patients per month (p = 0.0002), with the median rising from 9 (IQR 7-14) to 16 (IQR 13-21) patients. Monthly patients undergoing at least one invasive procedure increased from 4.9 to 8.0 (p = 0.0085). Monthly cancers increased from 3.0 to 3.8 (p = 0.3242), while monthly early-stage cancers rose from 1.4 to 2.4 (p = 0.125). Median time to diagnosis was 58 days (IQR 33-158) before and 57 days (IQR 27-85) after implementation (p = 0.26), with IQR narrowing from 125 days to 58 days. Implementation of the AI-enabled software was associated with significantly increased throughput of lung nodule patients and procedural volume. These results, observed prospectively post-implementation, suggest AI-assisted identification and triage can expand access to timely specialist review.